Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Chronic Weight Management
Interventions: ASC36 Injection A, for subcutaneous use, ASC36 Placebo Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use, ASC36 Placebo Injection B, for subcutaneous use; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Myeloma
Interventions: MRD Assessment; Other
Lead sponsor: Rajshekhar Chakraborty, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM; Device
Lead sponsor: Siemens Medical Solutions USA - CSG; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 764 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Conditions: Chronic Pain
Interventions: group acupuncture, Integrative Group Medical Visits; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma, Fatigue
Interventions: AYO light glasses (Experimental), AYO light glasses (Comparator); Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Hackensack, New Jersey • New York, New York

Conditions: Chronic Myelogenous Leukemia
Interventions: Asciminib, Bosutinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 10
States / cities: Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more

Conditions: Keloid
Interventions: RXI-109, Placebo; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Chronic Subdural Hematoma, cSDH, Chronic Subdural Hematomas
Interventions: Neuro endovascular embolic coil; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Valhalla, New York • Philadelphia, Pennsylvania

Conditions: Healthy Adult Participants
Interventions: GSM-779690T, Placebo; Drug · Other
Lead sponsor: Acta Pharmaceuticals; Industry
Eligibility: 20 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions: PACE Program; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Chapel Hill, North Carolina

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: Primary Ciliary Dyskinesia
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: treosulfan, fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, methotrexate; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Seattle, Washington

Conditions: Obesity
Interventions: AGBS; Device
Lead sponsor: Allurion Technologies; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Spinal Cord Injury, Quadriplegia
Interventions: NeuRx DPS; Device
Lead sponsor: Synapse Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 4
States / cities: Englewood, Colorado • Atlanta, Georgia • Cleveland, Ohio + 1 more

Conditions: Tuberous Sclerosis, Autism Disorder, Intellectual Disability
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 3 more

Conditions: Prostate Cancer
Interventions: Capivasertib, Enzalutamide, Abiraterone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Indianapolis, Indiana • Omaha, Nebraska • White Plains, New York + 2 more

Conditions: Respiratory Failure, Multiple Organ Failure
Interventions: PROOFcheck, Standard Care; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Jacksonville, Florida • Rochester, Minnesota • The Bronx, New York

Conditions: Migraine, Headache, Multiple Sclerosis, Insomnia
Interventions: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Stroke, Acute, Stroke Hemorrhagic, Hemiparesis, Hemiplegia, Cerebrovascular Accident
Interventions: ReWalk ReStore device; Device
Lead sponsor: ReWalk Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • West Orange, New Jersey + 2 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 15 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Emphysema, Alpha 1-Antitrypsin Deficiency
Interventions: Hyaluronic Acid Inhalation Solution, Placebo Inhalation Solution; Drug
Lead sponsor: Gerard Turino; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight

Non-invasive MRD Assessment in Multiple Myeloma

Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

Group-based Integrative Pain Management (IPMP+ Pilot)

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Prospective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy

A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants

Physical Activity and Community EmPOWERment Project

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Genetic Study of Patients With Primary Ciliary Dyskinesia

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Electrical Activation of The Diaphragm for Ventilatory Assist

Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Prevention of Severe Acute Respiratory Failure in Patients With PROOFCheck

RELAXaHEAD for Headache Patients (Phase II)

Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency